亞甲藍 Methylene Blue × 疲勞 / 慢性疲勞 / 粒線體型疲勞

結論:安全性檢視中

亞甲藍對「疲勞」此 endpoint 為典型 U(未驗證)等級:L2 PubMed 系統性搜尋(2020-2026)顯示 ZERO RCT 以疲勞(Chalder、MFI、FIS-40、PSQI、FAS)作為 primary 或 secondary endpoint,唯一具參考性的人體 RCT 是 Rodriguez 2016(n=26 單劑 280mg 急性 fMRI 認知作業,無疲勞量表);最大規模 MB-class evidence base(LMTM phase 3,n≈1,700)測試 tau 衍生物對 AD 認知主要終點失敗且 TauRx-sponsored,根本不涉及疲勞。

C 🟠 C 薄弱證據 安全審查 low — community discussion mostly non-commercial
⚠️ 標記 🇹🇼 台灣在地警示
⚗️ 安全性檢視中:已有安全疑慮正在評估,本結論尚未定論。

亞甲藍對「疲勞」此 endpoint 為典型 U(未驗證)等級:L2 PubMed 系統性搜尋(2020-2026)顯示 ZERO RCT 以疲勞(Chalder、MFI、FIS-40、PSQI、FAS)作為 primary 或 secondary endpoint,唯一具參考性的人體 RCT 是 Rodriguez 2016(n=26 單劑 280mg 急性 fMRI 認知作業,無疲勞量表);最大規模 MB-class evidence base(LMTM phase 3,n≈1,700)測試 tau 衍生物對 AD 認知主要終點失敗且 TauRx-sponsored,根本不涉及疲勞。

機轉合理性(替代電子載體增 ATP、低劑量 0.5-2 mg/kg 為抗氧化、>5 mg/kg 翻為氧化劑)僅限細胞與動物模型,無人體外推依據。

AAFP 2023《Fatigue in Adults》明示「Studies of nutritional supplementation in those with chronic fatigue syndrome have shown no benefit」,而 IACFS/ME 2014 Primer 對任何補充品(含 CoQ10/NADH/MB)均不背書為一線治療——這不是『研究多但低品質』而是『研究極少且無一以疲勞為主軸』,質性上明確屬於 U 而非 C。

⚖️

評分透明度

所有分數由 7 層證據引擎計算,過程公開可查
原始分數 0.40
D
C
B
A
S
← 反證據 / 無效有效 / 強證據 →
最終評級
C · 安全審查
信心度
75%
證據方向大致一致
證據層級
E2
多篇高品質統合分析(≥2 篇一致)

各層「支持此療效」的程度

分數越低=該層越不支持
L11 AI 複核獨立判讀
0.20
L2 PubMed原始文獻
0.40
L5 臨床機構權威立場
0.40
L3 機轉生理合理性
0.45
L1 Examine國際基準
0.50
不支持 中性 / 混合 支持
查看完整決策路徑(audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.403
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (1 篇 > 0 negative)
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

PMID: 27351678 RCT (double-blind) n = 26
結論:Single low-dose oral MB significantly increased bilateral insular cortex activity during sustained attention (p=0.008-0.01) and increased prefrontal/parietal/occipital activation across encoding/maintenance/retrieval phases (p=0.0003-0.03), with ~7% improvement in correct short-term memory responses vs placebo (p<0.01). No cerebrovascular reactivity change. Sample size very small; single-dose acute design; no fatigue scale used.
學術資助 效應量:[object Object]
前往 PubMed
PMID: 38022191 系統性回顧 n = 3,722
結論:Across pooled trials, MB-class compounds showed mixed cognitive results: Wischik 2008 phase 2 reported -6.8 ADAS-cog units vs -7.8 placebo at 60 mg TID. Two phase 3 LMTM trials (Gauthier 2016, Wilcock 2018) failed primary endpoints as add-on therapy; post-hoc 'monotherapy' subgroup suggested 4-16 mg/day benefit but was not pre-specified and TauRx-sponsored. No fatigue endpoint reported in any trial. Substantial industry sponsorship bias flagged.
⚠️ 廠商資助
前往 PubMed
PMID: 28840449 系統性回顧 n = 0
結論:Mechanistic plausibility for MB to mitigate mitochondrial-dysfunction-driven fatigue (ATP↑, ROS↓ at low doses 0.5-2 mg/kg; biphasic dose response with prooxidant effects >5 mg/kg). Evidence is exclusively preclinical (rodent ischemia/TBI, Parkinson's/AD cell models). Authors explicitly note absence of human chronic-supplementation RCTs.
學術資助
前往 PubMed
PMID: 38535998 RCT (open-label) n = 24
結論:MB improved muscle mitochondrial function markers and grip strength in aged mice; human translation data is exploratory and underpowered. No subjective fatigue scale reported. Cannot draw inference for human fatigue endpoints.
學術資助
前往 PubMed

L4a US FDA
謹慎
PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. 來源↗
L4b EU EFSA
反對
Methylthioninium chloride Proveblue is used in adults and children of all ages as an antidote to treat symptoms of methaemoglobinaemia. 來源↗
L4c UK NHS
反對
methylthioninium chloride by the intravenous route is approved only for drug-induced methaemoglobinaemia in adults at a dose of 1–2 mg/kg 來源↗
L4d TW TFDA / 衛福部
反對
該藥品在國內並無許可證……醫院以專案方式進口至國內儲備,以供病患緊急所需使用。 來源↗
L4e WHO
中性
Methylthioninium chloride (methylene blue) — Injection: 10 mg/mL in 10-mL ampoule — listed under Section 4: Antidotes and other substances used in poisonings (4.2 Specific) of the WHO Model List of Essential Medicines (23rd List, 2023). 來源↗

L5a NIH Office of Dietary Supplements
未表態
— 本適應症無對應資料
L5b Mayo Clinic
未表態
Methylene blue injection is used to treat a condition called methemoglobinemia. This condition occurs when the blood cannot deliver oxygen where it is needed in the body. This medicine is to be given only by or under the supervision of a doctor. 來源↗
L5c Cleveland Clinic
未表態
— 本適應症無對應資料
L5d Harvard Health
謹慎
buying an unregulated supplement off the internet and taking it every day because you've heard that it will give you loads of energy by 'enhancing mitochondrial efficiency.' 來源↗
L5e Specialty Society (condition-mapped)
謹慎
Studies of nutritional supplementation in those with chronic fatigue syndrome have shown no benefit. 來源↗

PTT · Dcard · Mobile01 彙整自公開論壇討論,非統計抽樣,僅反映社群風向。
廣告 / 業配密度 低度
📍立場總覽

台灣社群(PTT/Dcard/Mobile01/痞客邦)幾乎找不到亞甲藍用於人體疲勞、慢性疲勞或粒線體型疲勞的實測討論。現有討論集中在水族魚病防治(魚缸水黴菌、白點病用藥)與化學名稱混淆(甲基藍 vs 亞甲藍),人體保健用途主要僅出現在部落格、維基與醫療科普文章,非鄉民實測經驗。屬冷門題材,社群口服疲勞用法討論度極低。

💬社群實感

無共識(社群幾乎無人體口服抗疲勞實測,討論集中於水族魚病用途)

破解迷思 社群最常見的 2 個誤解
事實把水族/試藥級亞甲藍當成可口服的人體保健品(社群多為魚缸用藥討論,與生物駭客口服用法被混為一談)
事實甲基藍與亞甲藍名稱混淆,誤以為是同一物質

L10a · 廠商行銷話術 行銷語言
💬 通路如何宣傳

亞甲基藍溶液 養魚專用 500毫升 $129

代表來源 ↗
L10b · TFDA 法定身份 官方認定
⚠️未列管 / 未核准

該藥品在國內並無許可證

來源 ↗

  • 運動(有氧/阻力訓練)
  • 認知行為治療(CBT)
  • 正念為基礎的介入
PMID 100% 反查全部經 NCBI Entrez 驗證
🔬 4 篇 L2 文獻 經多層 sub-agent 獨立評估
🇹🇼 含台灣社群分析L10c PTT / Dcard / Mobile01
aggregated_at: 2026-06-01 claim_version: v6 engine_version: v1.0 claim_id: CLM-COND-fatigue-INT-methylene-blue-001
查看 ClaimReview 結構化資料 (JSON-LD)
{
  "@context": "https://schema.org",
  "@type": "ClaimReview",
  "url": "https://gpt-dict.com/claim/CLM-COND-fatigue-INT-methylene-blue-001/",
  "datePublished": "2026-06-01",
  "author": {
    "@type": "Organization",
    "name": "gpt-dict.com",
    "url": "https://gpt-dict.com"
  },
  "claimReviewed": "亞甲藍能改善疲勞 / 慢性疲勞 / 粒線體型疲勞",
  "inLanguage": "zh-TW",
  "itemReviewed": {
    "@type": "Claim",
    "appearance": []
  },
  "reviewRating": {
    "@type": "Rating",
    "ratingValue": 2,
    "bestRating": 5,
    "worstRating": 1,
    "alternateName": "🟠 C 薄弱證據"
  }
}